What is WINREVAIR prescribed for?
WINREVAIR is prescribed to treat adults with pulmonary arterial hypertension.
What is the name of the drug and what does it do?
WINREVAIR pronounced WIN-reh-vair, (generic name: sotatercept-csrk) is used to treat adults with pulmonary arterial hypertension (PAH), a condition where there is high blood pressure in the arteries of the lungs.
This drug helps patients exercise more easily, feel better in their daily activities, and lowers the risk of their condition getting worse.
How does it work?
WINREVAIR works by targeting specific pathways that cause the progression of PAH. The active ingredient, sotatercept-csrk, helps balance the signals that control growth and development in the blood vessels of the lungs.
This reduces the pressure in the lung arteries and improves heart and lung function.
What did the research discover?
Research found that WINREVAIR significantly improves the ability to exercise in people with PAH.
Clinical trials showed that patients taking WINREVAIR had fewer symptoms and a lower risk of their condition worsening.
This makes WINREVAIR a valuable option for managing PAH and enhancing the quality of life for patients.
What are some of the side effects?
- Headache
- Nosebleeds
- Rash
- Small red or purple spots on the skin (spider veins)
- Diarrhea
- Dizziness
- Redness of the skin
What are the dosage recommendations and how is it prescribed?
WINREVAIR is given as an injection under the skin every three weeks and the starting dose is 0.3 mg/kg.
The injection can be done in the stomach (away from the belly button), upper thigh, or upper arm. Patients or caregivers will be trained on how to properly prepare and give the injection at home.
It is very important to follow the healthcare provider’s instructions exactly. If you miss a dose and it’s within three days, take it as soon as possible.
If more than three days have passed, talk to your healthcare provider for advice on what to do next.
Source:
WINREVAIRTM (sotatercept-csrk) for injection, for subcutaneous use Initial U.S. Approval: 2024 [Internet]. U.S. Food and Drug Administration. 2024 cited 2024 Jul 15. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf
